Unknown

Dataset Information

0

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.


ABSTRACT: OBJECTIVE:The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy. DESIGN:A randomised, double-blind, multicentre, parallel-group study was conducted to verify the non-inferiority of vonoprazan 20?mg to lansoprazole 30?mg as part of first-line triple therapy (with amoxicillin 750?mg and clarithromycin 200 or 400?mg) in H pylori-positive patients with gastric or duodenal ulcer history. The first 50 patients failing first-line therapy with good compliance also received second-line vonoprazan-based triple therapy (with amoxicillin 750?mg and metronidazole 250?mg) as an open-label treatment. RESULTS:Of the 650 subjects randomly allocated to either first-line triple therapy, 641 subjects completed first-line therapy and 50 subjects completed second-line therapy. The first-line eradication rate (primary end point) was 92.6% (95% CI 89.2% to 95.2%) with vonoprazan versus 75.9% (95% CI 70.9% to 80.5%) with lansoprazole, with the difference being 16.7% (95% CI 11.2% to 22.1%) in favour of vonoprazan, thus confirming the non-inferiority of vonoprazan (p<0.0001). The second-line eradication rate (secondary end point) was also high (98.0%; 95% CI 89.4% to 99.9%) in those who received second-line therapy (n=50). Both first-line triple therapies were well tolerated with no notable differences. Second-line triple therapy was also well tolerated. CONCLUSION:Vonoprazan is effective as part of first-line triple therapy and as part of second-line triple therapy in H pylori-positive patients with a history of gastric or duodenal ulcer. TRIAL REGISTRATION NUMBER:NCT01505127.

SUBMITTER: Murakami K 

PROVIDER: S-EPMC5036253 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Murakami Kazunari K   Sakurai Yuuichi Y   Shiino Madoka M   Funao Nobuo N   Nishimura Akira A   Asaka Masahiro M  

Gut 20160302 9


<h4>Objective</h4>The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy.<h4>Design</h4>A randomised, double-blind, multicentre, parallel-group study was conducted to verify the non-inferiority of vonoprazan 20 mg to lansoprazole 30 mg as part of first-line triple therapy (with amoxicillin 750 mg and clarithromycin 200 or 400 mg) in H pylori-positive patie  ...[more]

Similar Datasets

| S-EPMC8298865 | biostudies-literature
| S-EPMC5557549 | biostudies-other
| S-EPMC4902499 | biostudies-literature
| S-EPMC10196117 | biostudies-literature
| S-EPMC4738414 | biostudies-literature
| S-EPMC9289827 | biostudies-literature
| S-EPMC7008067 | biostudies-literature
| S-EPMC9291775 | biostudies-literature
| S-EPMC7675913 | biostudies-literature
| S-EPMC9278030 | biostudies-literature